OTCMKTS:BVNRY Bavarian Nordic Q2 2026 Earnings Report $10.57 +0.02 (+0.14%) As of 12:35 PM Eastern ProfileEarnings History Bavarian Nordic EPS ResultsActual EPS$0.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABavarian Nordic Revenue ResultsActual Revenue$316.47 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABavarian Nordic Announcement DetailsQuarterQ2 2026Date8/21/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Bavarian Nordic Earnings HeadlinesBavarian Nordic (OTCMKTS:BVNRY) Short Interest UpdateSeptember 15 at 4:21 AM | americanbankingnews.comBavarian Nordic Earnings Call Signals Profitable GrowthAugust 29, 2026 | tipranks.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 18 at 1:00 AM | Digest Publishing (Ad)Bavarian Nordic A/S (BVNRY) Q2 2026 Earnings Call TranscriptAugust 21, 2026 | seekingalpha.comGlobal warming widens spread of TBE, chikungunya, Bavarian Nordic boss saysAugust 21, 2026 | reuters.comBavarian Nordic AS ADR BVNRYJuly 4, 2026 | morningstar.comMSee More Bavarian Nordic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email. Email Address About Bavarian NordicBavarian Nordic (OTCMKTS:BVNRY) A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets. Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis. Its portfolio includes vaccines used in routine, travel and outbreak-response settings. Founded in 1994 and headquartered in Hellerup, Denmark, Bavarian Nordic has developed specialized vaccine production capabilities and works with public-sector customers on preparedness for infectious disease threats. The company also conducts research and development aimed at expanding its vaccine portfolio and addressing additional unmet needs in infectious disease prevention.View Bavarian Nordic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
